The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Open accessAbstract
The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–257 of 257
Soria, J., Adjei, A. A., Bahleda, R., Besse, B., Ferté, C., Planchard, D., Zhou, J., Ware, J. A., Morrissey, K. M., Shankar, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.027 · Cited by 42
Pazarentzos, E., Giannikopoulos, P., Hrustanovic, G., John, J. S., Olivas, V. R., Gubens, M. A., Balassanian, R., Weissman, J. S., Polkinghorn, W. R., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.173 · Cited by 41
Hudson, K., Hancox, U. J., Trigwell, C. B., McEwen, R. K., Polanska, U. M., Nikolaou, M., Gutierrez, P. M., Avivar‐Valderas, A., Delpuech, O., Dudley, P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0687 · Cited by 41
The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
Shi, F., Zhang, J., Liu, H., Wu, L., Jiang, H., Wu, Q., Liu, T., Lou, M., & Wu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.23091 · Cited by 41
Flinn, I. W., Cherry, M. A., Maris, M. B., Matous, J., Berdeja, J. G., & Patel, M. R. (2019) · American Journal of Hematology · doi:10.1002/ajh.25634 · Cited by 41
Rosenthal, M. A., Clément, P. M., Campone, M., Gil‐Gil, M., DeGroot, J. F., Chinot, O. L., Idbaïh, A., Gan, H. K., Raizer, J. J., Wen, P. Y., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000672 · Cited by 41
Coleman, M., Belada, D., Casasnovas, O., Gressin, R., Lee, H., Mehta, A., Munoz, J. L., Verhoef, G. E. G., Corrado, C., DeMarini, D. J., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1832660 · Cited by 41
Kim, R. D., Alberts, S. R., Peña, C. E., Genvresse, I., Ajavon‐Hartmann, A., Xia, C., Kelly, A. T., & Grilley‐Olson, J. E. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.428 · Cited by 40
Ruicci, K. M., Pinto, N. C., Khan, M. I., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.010 · Cited by 40
Morschhauser, F., Machiels, J., Salles, G. A., Rottey, S., Rule, S. A., Cunningham, D., Peyrade, F., Fruchart, C., Arkenau, H., Genvresse, I., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0466 · Cited by 40
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
Zhou, H., Yu, C., Kong, L., Xu, X., Yan, J., Li, Y., An, T., Gong, L., Gong, Y., Zhu, H., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0674-5 · Cited by 39
Soria, J., LoRusso, P. A., Bahleda, R., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0449 · Cited by 38
Doi, T., Fuse, N., Yoshino, T., Kojima, T., Bando, H., Miyamoto, H., Kaneko, M., Osada, M., & Ohtsu, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3198-0 · Cited by 38
Croessmann, S., Sheehan, J. H., Lee, K., Sliwoski, G. R., He, J., Nagy, R. J., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2141 · Cited by 38
Radovich, M., Solzak, J. P., Wang, C. J., Hancock, B. A., Badve, S., Althouse, S. K., Bray, S. M., Storniolo, A. M., Ballinger, T. J., Schneider, B. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3078 · Cited by 38
Blackwell, K., Burris, H. A., Gómez, P., Henry, N. L., Isakoff, S. J., Campana, F., Gao, L., Jiang, J., Macé, S., & Tolaney, S. M. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3615-9 · Cited by 37
Colombo, I., Genta, S., Martorana, F., Guidi, M., Frattini, M., Samartzis, E. P., Brandt, S., Gaggetta, S., Moser, L., Pascale, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1402 · Cited by 36
Cook, G. W., Benton, M. G., Akerley, W., Mayhew, G. F., Moehlenkamp, C., Raterman, D., Burgess, D. L., Rowell, W. J., Lambert, C. C., Eng, K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226340 · Cited by 35
Qian, X.-J., Li, Y.-T., Yu, Y., Yang, F., Deng, R., Ji, J., Jiao, L., Li, X., Wu, R.-Y., Chen, W.-D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3016 · Cited by 34
Piha-Paul, S. A., Taylor, M. H., Spitz, D. L., Schwartzberg, L. S., Beck, J. T., Bauer, T. M., Meric‐Bernstam, F., Purkayastha, D., Karpiak, L., Szpakowski, S., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27251 · Cited by 34
NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K/AKT pathway.
Han, X., Li, J., & Zg, Z. (2018) · PubMed · doi:10.26355/eurrev_201810_16053 · Cited by 33
Yamamoto, N., Fujiwara, Y., Tamura, K., Kondo, S., Iwasa, S., Tanabe, Y., Horiike, A., Yanagitani, N., Kitazono, S., Inatani, M., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0382-3 · Cited by 32
Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression
Gong, J., Qi, X.-F., Zhang, Y., Yu, Y., Lin, X., Li, H., & Hu, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.004 · Cited by 32
MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Wu, S., Wang, S., Zheng, S., Verhaak, R. G. W., Koul, D., & Yung, W. K. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0857 · Cited by 30
Wheler, J. J., Mutch, D. G., Lager, J. J., Castell, C., Liu, L., Jiang, J., & Traynor, A. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0257 · Cited by 30
Leong, S., Moss, R. A., Bowles, D. W., Ware, J. A., Zhou, J., Spoerke, J. M., Lackner, M. R., Shankar, G., Schutzman, J. L., van der Noll, R., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0090 · Cited by 30
Wu, C., Hung, C., Lusvarghi, S., Huang, Y.-H., Tseng, P.-J., Hung, T., Yu, J., & Ambudkar, S. V. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114137 · Cited by 29
Arkenau, H., Mateo, J., Lemech, C., Infante, J. R., Burris, H. A., Bang, Y., Eder, J. P., Herbst, R. S., Sharma, S., Chung, H. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2514 · Cited by 28
Cloughesy, T. F., Mischel, P. S., Omuro, A. M. P., Prados, M. D., Wen, P. Y., Wu, B., Rockich, K. T., Xu, Y., Lager, J. J., & Mellinghoff, I. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2012 · Cited by 26
Goodwin, R. A., Jonker, D. J., Chen, E. X., Kennecke, H. F., Cabanero, M., Tsao, M., Vickers, M. M., Bohemier, C., Lim, H. J., Ritter, H. D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00814-3 · Cited by 26
Koh, K. X., Tan, G. H., Low, S. H. H., Omar, M. F. M., Han, M. J., Iacopetta, B. J., Soo, R. A., Beloueche‐Babari, M., Bhattacharya, B., & Soong, R. (2017) · Oncotarget · doi:10.18632/oncotarget.22655 · Cited by 25
Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
Münster, P. N., Hamilton, E. P., García‐Estévez, L., Boer, R. H. D., Mayer, I. A., Campone, M., Asano, S., Bhansali, S. G., Zhang, V. Y., Hewes, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.26_suppl.143 · Cited by 24
Gelderblom, H. A. J., Jones, R. L., George, S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0769-y · Cited by 24
Algazi, A. P., Rotow, J., Posch, C., Ortiz‐Urda, S., Pelayo, A., Munster, P. N., & Daud, A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12777 · Cited by 23
Elwy, F., Helwa, R., Leithy, A. A. E., Shehab El din, Z., Assem, M., & Hassan, N. H. A. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.1.57 · Cited by 21
Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE
Luo, L. E., Zhong, Q., Guo, S., Zhang, C., Zhang, Q., Zheng, S., He, L., & Wang, G. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127258 · Cited by 20
Mishra, R., Yuan, L., Patel, H. M., Karve, A. S., Zhu, H., White, A., Alanazi, S., Desai, P. B., Merino, E. J., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042088 · Cited by 20
Self-citationProstate Power Play: Does Pik3ca Accelerate Pten -Deficient Cancer Progression?
Triscott, J., & Rubin, M. A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0369 · Cited by 19
Eyre, T. A., Preston, G., Kagdi, H., Islam, A. M., Nicholson, T., Smith, H., Cursley, A., Ramroth, H., Xing, G., Gu, L., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17475 · Cited by 19
Hyman, D. M., Tran, B., Jaime, J. C., Garralda, E., Machiels, J., Schellens, J. H. M., Bedard, P. L., Campone, M., Cassier, P. A., Sarantopoulos, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2500 · Cited by 18
Smyth, L. M., Monson, K. R., Jhaveri, K. L., Drilon, A. E. D. C., Li, B. T., Abida, W. M., Iyer, G., Gerecitano, J. F., Gounder, M. M., Harding, J. J., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0445-0 · Cited by 16
Jain, S., Santa-Maria, C. A., RADEMAKER, A. W., Giles, F. J., Cristofanilli, M., & Gradishar, W. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1026 · Cited by 16
Cruz, C., Schüler, M., Machiels, J., Hess, D., Paz-Ares, L. G., Awada, A. H., von Moos, R., Steeghs, N., Rodon, J. A., Mesmaeker, P. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.627 · Cited by 15
Han, N., Jiang, Y., Gai, Y., Liu, Q., Yuan, L., Wang, Y., Li, M., Zhang, Y., & Lan, X. (2019) · Contrast Media & Molecular Imaging · doi:10.1155/2019/1760184 · Cited by 15
Mehnert, J. M., Edelman, G. M., Stein, M. N., Camisa, H., Lager, J. J., Dedieu, J.-F., Ghuysen, A.-F., Sharma, J., Liu, L., & LoRusso, P. M. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0467-7 · Cited by 14
Owonikoko, T. K., Harvey, R. D., Carthon, B. C., Chen, Z., Lewis, C. M., Collins, H., Zhang, C., Lawson, D. H., Alese, O. B., Bilen, M. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2697 · Cited by 14
Chu, Q. S.-C., Mahipal, A., Schüler, M., de Braud, F., Dirix, L. Y., Rampersad, A., Zhou, J., Wu, Y., Kalambakas, S. A., & Wen, P. Y. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu331.5 · Cited by 13
Toyoda, M., Watanabe, K., Amagasaki, T., Natsume, K., Takeuchi, H., Quadt, C., Shirao, K., & Minami, H. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3725-2 · Cited by 12
Brown, J. R., Davids, M. S., Rodon, J. A., Abrisqueta, P., DeCillis, A. P., Rockich, K. T., Égile, C., Kelly, A., Xu, Y., Lager, J. J., et al. (2011) · Blood · doi:10.1182/blood.v118.21.2683.2683 · Cited by 11
Zhu, H., Mishra, R., Yuan, L., AbdulSalam, S. F., Liu, J. L., Gray, G., Sterling, A., Wunderlich, M., Figueroa, J. A. L., Garrett, J. T., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900481 · Cited by 11
Self-citationBaselga, J. M., Curigliano, G., Martín, M., André, F., Beck, J. T., Tortora, G., Wilke, C., Charbonnier, L., Blumenstein, L., Donnet, V., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct061 · Cited by 10
Bono, J. S. D., Hansen, A. R., Choudhury, A. D., Cook, N., Heath, E. I., Higano, C. S., Linch, M. D., Martín-Liberal, J., Rathkopf, D. E., Wisinski, K. B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy284.042 · Cited by 9
Kondo, S., Tajimi, M., Funai, T., Inoue, K., Asou, H., Ranka, V. K., Wacheck, V., & Doi, T. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00968-5 · Cited by 8
Fukuhara, N., Kinoshita, T., Yamamoto, K., Nagai, H., Izutsu, K., Yamamoto, G., Bhargava, P., Rajakumaraswamy, N., Humeniuk, R., Mathias, A. A., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa153 · Cited by 8
Assouline, S. E., Amrein, L., Aloyz, R. S., Banerji, V., Caplan, S. N., Owen, C., Hasegawa, W. S., Robinson, S., Shivakumar, S., Prica, A. A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1734594 · Cited by 7
Abramson, V. G., Oliveira, M., Cervantes, A. M. R., Wildiers, H. P. M. W., Patel, M. R., Bauer, T. M., Bedard, P. L., Becerra, C. R., Richey, S. L., Wei, M. C., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05360-3 · Cited by 5
Wilk, A. M., Fouquerel, E., Johnston, B. E., Trammell, S. A. J., Schambeau, L., Andrews, J., Pannell, L. K., Cooper, S. J., Brenner, C., & Sobol, R. W. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4 · Cited by 4
Cited by
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89942 · Cited by 280
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Metadata
- Authors
- Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-27
- Volume
- 22
- Issue
- 7
- Pages
- 3464
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3141987310
- Cited by
- 281
- References
- 257
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.